The Food and Drug Administration has approved special handling instructions to allow health care providers to use certain opioid and other intravenous drug products made by Hospira that were on hold due to low potential for a manufacturing defect but are in short supply. Health care providers should not use the Carpuject Luer Lock Glass Syringe products if the cartridges are visibly damaged or contain particulate matter, according to the instructions. Hospitals and health systems continue to experience critical shortages of a number of injectable opioid medications. Commenting this month on a Drug Enforcement Administration proposed rule on controlled substances quotas, AHA urged the agency to include drug shortages as a factor when setting and adjusting aggregate and individual manufacturers’ production quotas for controlled substances, and joined with the American Society of Health-System Pharmacists and others in requesting similar changes to the proposed rule.

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…